ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer
Identifieur interne : 000340 ( France/Analysis ); précédent : 000339; suivant : 000341ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer
Auteurs : Lindsay A. Renfro [États-Unis] ; Axel Grothey [États-Unis] ; YUAN XUE [États-Unis] ; Leonard B. Saltz [États-Unis, France] ; Thierry Andre [France] ; Chris Twelves [Royaume-Uni] ; Roberto Labianca [Italie] ; Carmen J. Allegra [États-Unis] ; Steven R. Alberts [États-Unis] ; Charles L. Loprinzi [États-Unis] ; Greg Yothers [États-Unis] ; Daniel J. Sargent [États-Unis]Source :
- Journal of the National Cancer Institute [ 0027-8874 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Estimation de Kaplan-Meier, Femelle, Grading des tumeurs, Humains, Internet, Logiciel, Mâle, Métastase lymphatique, Pronostic, Récidive tumorale locale (diagnostic), Stade de la tumeur, Sujet âgé, Survie sans rechute, Tumeurs du côlon (anatomopathologie), Tumeurs du côlon (diagnostic), Tumeurs du côlon (mortalité), Types de pratiques des médecins (tendances), Valeur prédictive des tests, États-Unis d'Amérique.
- MESH :
- anatomopathologie : Tumeurs du côlon.
- diagnostic : Récidive tumorale locale, Tumeurs du côlon.
- mortalité : Tumeurs du côlon.
- tendances : Types de pratiques des médecins.
- Pascal (Inist)
- Adulte d'âge moyen, Cancer du côlon, Estimation de Kaplan-Meier, Femelle, Grading des tumeurs, Humains, Internet, Facteur prédictif, Logiciel, Mâle, Métastase lymphatique, Pronostic, Prédiction, Récidive, Stade de la tumeur, Sujet âgé, Survie, Stade avancé, Cancérologie, Stade localement avancé, Survie sans rechute, Valeur prédictive des tests, États-Unis d'Amérique.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Advanced stage, Aged, Cancerology, Colon cancer, Colonic Neoplasms (diagnosis), Colonic Neoplasms (mortality), Colonic Neoplasms (pathology), Disease-Free Survival, Female, Humans, Internet, Kaplan-Meier Estimate, Locally advanced stage, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local (diagnosis), Neoplasm Staging, Practice Patterns, Physicians' (trends), Prediction, Predictive Value of Tests, Predictive factor, Prognosis, Relapse, Software, Survival, United States.
- MESH :
- geographic : United States.
- diagnosis : Colonic Neoplasms, Neoplasm Recurrence, Local.
- mortality : Colonic Neoplasms.
- pathology : Colonic Neoplasms.
- trends : Practice Patterns, Physicians'.
- Aged, Disease-Free Survival, Female, Humans, Internet, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Predictive Value of Tests, Prognosis, Software.
Abstract
Background Current prognostic tools in colon cancer use relatively few patient characteristics. We constructed and validated clinical calculators for overall survival (OS) and time to recurrence (TTR) for stage III colon cancer and compared their performance against an existing tool (Numeracy) and American Joint Committee on Cancer (AJCC) version 7 staging. Methods Data from 15936 stage III patients accrued to phase III clinical trials since 1989 were used to construct Cox models forTTR and OS. Variables included age, sex, race, body mass index, performance status, tumor grade, tumor stage, ratio of positive lymph nodes to nodes examined, number and location of primary tumors, and adjuvant treatment (fluoropyrimidine single agent or in combination). Missing data were imputed, and final models internally validated for optimism-corrected calibration and discrimination and compared with AJCC. External validation and comparisons against Numeracy were performed using stage III patients from NSABP trial C-08. All statistical tests were two-sided. Results All variables were statistically and clinically significant for OS prediction, while age and race did not predict TTR. No meaningful interactions existed. Models for OS andTTR were well calibrated and associated with C-indices of 0.66 and 0.65, respectively, compared with C-indices of 0.58 and 0.59 for AJCC. These tools, available online, better predicted patient outcomes than Numeracy, both overall and within patient subgroups, in external validation. Conclusions The proposed ACCENT calculators are internally and externally valid, better discriminate patient risk than AJCC version 7 staging, and better predict patient outcomes than Numeracy. These tools have replaced Numeracy for online clinical use and will aid prognostication and patient/physician communication.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000157
- to stream PascalFrancis, to step Curation: 004434
- to stream PascalFrancis, to step Checkpoint: 000D53
- to stream Main, to step Merge: 005C76
- to stream Pmc, to step Corpus: 000B05
- to stream Pmc, to step Curation: 000A80
- to stream Pmc, to step Checkpoint: 001D50
- to stream PubMed, to step Corpus: 001803
- to stream PubMed, to step Curation: 001796
- to stream PubMed, to step Checkpoint: 001796
- to stream Ncbi, to step Merge: 003C55
- to stream Ncbi, to step Curation: 003C55
- to stream Ncbi, to step Checkpoint: 003C55
- to stream Main, to step Merge: 004410
- to stream Main, to step Curation: 005944
- to stream Main, to step Exploration: 005944
- to stream France, to step Extraction: 000340
Links to Exploration step
Pascal:15-0027078Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer</title><author><name sortKey="Renfro, Lindsay A" sort="Renfro, Lindsay A" uniqKey="Renfro L" first="Lindsay A." last="Renfro">Lindsay A. Renfro</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biomedical Statistics and Informatics, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Grothey, Axel" sort="Grothey, Axel" uniqKey="Grothey A" first="Axel" last="Grothey">Axel Grothey</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Oncology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Yuan Xue" sort="Yuan Xue" uniqKey="Yuan Xue" last="Yuan Xue">YUAN XUE</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Statistics, University of Virginia</s1><s2>Charlottesville, VA</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Charlottesville, VA</wicri:noRegion></affiliation></author><author><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B." last="Saltz">Leonard B. Saltz</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New York, NY</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hôpital Saint Antoine</s1><s2>Paris</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Pierre and Marie Curie University</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Twelves, Chris" sort="Twelves, Chris" uniqKey="Twelves C" first="Chris" last="Twelves">Chris Twelves</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Leeds Institute of Cancer and Pathology, University of Leeds and St. James's University Hospital, Leeds Cancer Research UK Centre</s1><s3>GBR</s3><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Leeds Institute of Cancer and Pathology, University of Leeds and St. James's University Hospital, Leeds Cancer Research UK Centre</wicri:noRegion></affiliation></author><author><name sortKey="Labianca, Roberto" sort="Labianca, Roberto" uniqKey="Labianca R" first="Roberto" last="Labianca">Roberto Labianca</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Oncology Unit, Ospedale Giovanni XXIII</s1><s2>Bergamo</s2><s3>ITA</s3><sZ>7 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Bergamo</wicri:noRegion></affiliation></author><author><name sortKey="Allegra, Carmen J" sort="Allegra, Carmen J" uniqKey="Allegra C" first="Carmen J." last="Allegra">Carmen J. Allegra</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Division of Hematology and Oncology, University of Florida</s1><s2>Gainesville, FL</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Gainesville, FL</wicri:noRegion></affiliation></author><author><name sortKey="Alberts, Steven R" sort="Alberts, Steven R" uniqKey="Alberts S" first="Steven R." last="Alberts">Steven R. Alberts</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Oncology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Loprinzi, Charles L" sort="Loprinzi, Charles L" uniqKey="Loprinzi C" first="Charles L." last="Loprinzi">Charles L. Loprinzi</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Oncology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>National Surgical Adjuvant Breast and Bowel Project Biostatistical Center</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>National Surgical Adjuvant Breast and Bowel Project Biostatistical Center</wicri:noRegion></affiliation></author><author><name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biomedical Statistics and Informatics, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">15-0027078</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 15-0027078 INIST</idno><idno type="RBID">Pascal:15-0027078</idno><idno type="wicri:Area/PascalFrancis/Corpus">000157</idno><idno type="wicri:Area/PascalFrancis/Curation">004434</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000D53</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D53</idno><idno type="wicri:doubleKey">0027-8874:2014:Renfro L:accent:based:web</idno><idno type="wicri:Area/Main/Merge">005C76</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334801</idno><idno type="RBID">PMC:4334801</idno><idno type="wicri:Area/Pmc/Corpus">000B05</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B05</idno><idno type="wicri:Area/Pmc/Curation">000A80</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000A80</idno><idno type="wicri:Area/Pmc/Checkpoint">001D50</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001D50</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001803</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001803</idno><idno type="wicri:Area/PubMed/Curation">001796</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001796</idno><idno type="wicri:Area/PubMed/Checkpoint">001796</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001796</idno><idno type="wicri:Area/Ncbi/Merge">003C55</idno><idno type="wicri:Area/Ncbi/Curation">003C55</idno><idno type="wicri:Area/Ncbi/Checkpoint">003C55</idno><idno type="wicri:doubleKey">0027-8874:2014:Renfro L:accent:based:web</idno><idno type="wicri:Area/Main/Merge">004410</idno><idno type="wicri:Area/Main/Curation">005944</idno><idno type="wicri:Area/Main/Exploration">005944</idno><idno type="wicri:Area/France/Extraction">000340</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer</title><author><name sortKey="Renfro, Lindsay A" sort="Renfro, Lindsay A" uniqKey="Renfro L" first="Lindsay A." last="Renfro">Lindsay A. Renfro</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biomedical Statistics and Informatics, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Grothey, Axel" sort="Grothey, Axel" uniqKey="Grothey A" first="Axel" last="Grothey">Axel Grothey</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Oncology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Yuan Xue" sort="Yuan Xue" uniqKey="Yuan Xue" last="Yuan Xue">YUAN XUE</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Statistics, University of Virginia</s1><s2>Charlottesville, VA</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Charlottesville, VA</wicri:noRegion></affiliation></author><author><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B." last="Saltz">Leonard B. Saltz</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New York, NY</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hôpital Saint Antoine</s1><s2>Paris</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Pierre and Marie Curie University</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Twelves, Chris" sort="Twelves, Chris" uniqKey="Twelves C" first="Chris" last="Twelves">Chris Twelves</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Leeds Institute of Cancer and Pathology, University of Leeds and St. James's University Hospital, Leeds Cancer Research UK Centre</s1><s3>GBR</s3><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Leeds Institute of Cancer and Pathology, University of Leeds and St. James's University Hospital, Leeds Cancer Research UK Centre</wicri:noRegion></affiliation></author><author><name sortKey="Labianca, Roberto" sort="Labianca, Roberto" uniqKey="Labianca R" first="Roberto" last="Labianca">Roberto Labianca</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Oncology Unit, Ospedale Giovanni XXIII</s1><s2>Bergamo</s2><s3>ITA</s3><sZ>7 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Bergamo</wicri:noRegion></affiliation></author><author><name sortKey="Allegra, Carmen J" sort="Allegra, Carmen J" uniqKey="Allegra C" first="Carmen J." last="Allegra">Carmen J. Allegra</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Division of Hematology and Oncology, University of Florida</s1><s2>Gainesville, FL</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Gainesville, FL</wicri:noRegion></affiliation></author><author><name sortKey="Alberts, Steven R" sort="Alberts, Steven R" uniqKey="Alberts S" first="Steven R." last="Alberts">Steven R. Alberts</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Oncology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Loprinzi, Charles L" sort="Loprinzi, Charles L" uniqKey="Loprinzi C" first="Charles L." last="Loprinzi">Charles L. Loprinzi</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Oncology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>National Surgical Adjuvant Breast and Bowel Project Biostatistical Center</s1><s2>Pittsburgh, PA</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>National Surgical Adjuvant Breast and Bowel Project Biostatistical Center</wicri:noRegion></affiliation></author><author><name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biomedical Statistics and Informatics, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Journal of the National Cancer Institute</title><title level="j" type="abbreviated">J. Natl. Cancer Inst.</title><idno type="ISSN">0027-8874</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of the National Cancer Institute</title><title level="j" type="abbreviated">J. Natl. Cancer Inst.</title><idno type="ISSN">0027-8874</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Aged</term><term>Cancerology</term><term>Colon cancer</term><term>Colonic Neoplasms (diagnosis)</term><term>Colonic Neoplasms (mortality)</term><term>Colonic Neoplasms (pathology)</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Internet</term><term>Kaplan-Meier Estimate</term><term>Locally advanced stage</term><term>Lymphatic Metastasis</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Neoplasm Recurrence, Local (diagnosis)</term><term>Neoplasm Staging</term><term>Practice Patterns, Physicians' (trends)</term><term>Prediction</term><term>Predictive Value of Tests</term><term>Predictive factor</term><term>Prognosis</term><term>Relapse</term><term>Software</term><term>Survival</term><term>United States</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Grading des tumeurs</term><term>Humains</term><term>Internet</term><term>Logiciel</term><term>Mâle</term><term>Métastase lymphatique</term><term>Pronostic</term><term>Récidive tumorale locale (diagnostic)</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Tumeurs du côlon (anatomopathologie)</term><term>Tumeurs du côlon (diagnostic)</term><term>Tumeurs du côlon (mortalité)</term><term>Types de pratiques des médecins (tendances)</term><term>Valeur prédictive des tests</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du côlon</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Colonic Neoplasms</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Récidive tumorale locale</term><term>Tumeurs du côlon</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Colonic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du côlon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colonic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Types de pratiques des médecins</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Practice Patterns, Physicians'</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Internet</term><term>Kaplan-Meier Estimate</term><term>Lymphatic Metastasis</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Neoplasm Staging</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Software</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Cancer du côlon</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Grading des tumeurs</term><term>Humains</term><term>Internet</term><term>Facteur prédictif</term><term>Logiciel</term><term>Mâle</term><term>Métastase lymphatique</term><term>Pronostic</term><term>Prédiction</term><term>Récidive</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Survie</term><term>Stade avancé</term><term>Cancérologie</term><term>Stade localement avancé</term><term>Survie sans rechute</term><term>Valeur prédictive des tests</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background Current prognostic tools in colon cancer use relatively few patient characteristics. We constructed and validated clinical calculators for overall survival (OS) and time to recurrence (TTR) for stage III colon cancer and compared their performance against an existing tool (Numeracy) and American Joint Committee on Cancer (AJCC) version 7 staging. Methods Data from 15936 stage III patients accrued to phase III clinical trials since 1989 were used to construct Cox models forTTR and OS. Variables included age, sex, race, body mass index, performance status, tumor grade, tumor stage, ratio of positive lymph nodes to nodes examined, number and location of primary tumors, and adjuvant treatment (fluoropyrimidine single agent or in combination). Missing data were imputed, and final models internally validated for optimism-corrected calibration and discrimination and compared with AJCC. External validation and comparisons against Numeracy were performed using stage III patients from NSABP trial C-08. All statistical tests were two-sided. Results All variables were statistically and clinically significant for OS prediction, while age and race did not predict TTR. No meaningful interactions existed. Models for OS andTTR were well calibrated and associated with C-indices of 0.66 and 0.65, respectively, compared with C-indices of 0.58 and 0.59 for AJCC. These tools, available online, better predicted patient outcomes than Numeracy, both overall and within patient subgroups, in external validation. Conclusions The proposed ACCENT calculators are internally and externally valid, better discriminate patient risk than AJCC version 7 staging, and better predict patient outcomes than Numeracy. These tools have replaced Numeracy for online clinical use and will aid prognostication and patient/physician communication.</div></front></TEI><affiliations><list><country><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="États-Unis"><noRegion><name sortKey="Renfro, Lindsay A" sort="Renfro, Lindsay A" uniqKey="Renfro L" first="Lindsay A." last="Renfro">Lindsay A. Renfro</name></noRegion><name sortKey="Alberts, Steven R" sort="Alberts, Steven R" uniqKey="Alberts S" first="Steven R." last="Alberts">Steven R. Alberts</name><name sortKey="Allegra, Carmen J" sort="Allegra, Carmen J" uniqKey="Allegra C" first="Carmen J." last="Allegra">Carmen J. Allegra</name><name sortKey="Grothey, Axel" sort="Grothey, Axel" uniqKey="Grothey A" first="Axel" last="Grothey">Axel Grothey</name><name sortKey="Loprinzi, Charles L" sort="Loprinzi, Charles L" uniqKey="Loprinzi C" first="Charles L." last="Loprinzi">Charles L. Loprinzi</name><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B." last="Saltz">Leonard B. Saltz</name><name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name><name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name><name sortKey="Yuan Xue" sort="Yuan Xue" uniqKey="Yuan Xue" last="Yuan Xue">YUAN XUE</name></country><country name="France"><region name="Île-de-France"><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B." last="Saltz">Leonard B. Saltz</name></region><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Twelves, Chris" sort="Twelves, Chris" uniqKey="Twelves C" first="Chris" last="Twelves">Chris Twelves</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Labianca, Roberto" sort="Labianca, Roberto" uniqKey="Labianca R" first="Roberto" last="Labianca">Roberto Labianca</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000340 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000340 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= France
|étape= Analysis
|type= RBID
|clé= Pascal:15-0027078
|texte= ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer
}}
| This area was generated with Dilib version V0.6.38. |  |